加拿大Caprion Proteomics
Caprion Pharmaceuticals Inc. (蒙特利尔，Montreal)宣布和ICOS Corporation公司进行一项新增的研究合作案。新的合作合约主要是采用Caprion公司的CellCarta(R) proteomics discovery platform蛋白质体学研发科技平台，应用在生物指标分子开发方面。Caprion公司将配合ICOS Corporation公司在临床前的癌症研究计划，去找寻血浆中可以作为药物动力学的分子。Caprion公司这项有专利的蛋白质体学研发科技平台，可以很有系统性的把在组织中或血浆中所找到的蛋白质群进行整理归类，以确定其基因表现和蛋白质本身的特性。此外，Caprion公司目前正在以生物指标开发技术，也在其它一些医学应用方向，提供其它一些医药和生技公司项目研究方面的服务。


Caprion’s leading and proprietary proteomics discovery technologies - CellCarta® - enable the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that can significantly reduce risk and enhance clinical development productivity and decision making in pharmaceutical research.

--------------------------------------------------------------------------------

CellCarta® Discovery Platform
Caprion’s proteomics discovery platform - CellCarta® - is the leading means for profiling proteins in solid tissues and plasma. CellCarta® is a proprietary, state-of-the-art proteomics technology platform that serves as an engine for unparalleled disease target identification, predictive medicine and the creation of a proprietary therapeutic product pipeline. The power of Caprion’s technology has been successfully leveraged to secure multiple, platform-validating, revenue generating partnerships surrounding oncology therapeutic target identification and clinical biomarker discovery.